logo

I-Mab (IMAB)



Trade IMAB now with
  Date
  Headline
8/30/2022 6:15:12 AM I-Mab H1 Net Loss Per Share RMB5.54/$0.83; Net Loss Per ADS RMB12.74/$1.90
8/23/2022 9:16:24 AM I-Mab Says May Repurchase Up To US$40 Mln Of ADSs In Aggregate
7/22/2022 8:05:25 AM I-Mab :First Patient Dosed In Phase 1 Trial Of Claudin 18.2 &4-1BB Bispecific Antibody TJ-CD4B In Solid Tumors In China
6/15/2022 8:43:08 AM I-Mab Partner MorphoSys Announces License Agreements For Felzartamab And TJ210
5/31/2022 8:10:46 AM I-Mab Completes Patient Enrollment In Phase III Trial Of Eftansomatropin Alfa For Pediatric Growth Hormone Deficiency
3/29/2022 6:14:55 AM I-Mab FY Loss Per Share RMB 13.35/$2.09 Vs RMB 3.51 Last Year
3/3/2022 8:15:06 AM I-Mab Gets FDA Orphan Drug Designation For Claudin 18.2 X 4-1BB Bispecific Antibody TJ-CD4B For Gastric Cancer Treatment
1/18/2022 8:27:07 AM I-Mab: First Patient Dosed In China Phase 2 Trial Of Lemzoparlimab With Toripalimab With Advanced Solid Tumors
1/12/2022 8:05:09 AM I-Mab Reports First Patient Dosed In China Phase 2 Trial Of Efineptakin Alfa-Pembrolizumab In Advanced Solid Tumors
12/27/2021 8:02:18 AM I-Mab Unveils IND Approval From China NMPA For Phase 2 Trial Of Enoblituzumab With Pembrolizumab In Solid Tumors
12/15/2021 8:11:45 AM I-Mab Receives IND Approval For Phase 1 Trial Of Bispecific Antibody TJ-CD4B In Solid Tumors In China
12/14/2021 6:02:25 AM I-Mab Presents Interim Data Of Lemzoparlimab With Rituximab In Relapsed And Refractory Non-Hodgkin Lymphoma At ASH
12/8/2021 8:09:29 AM I-Mab : First Patient Dosed In U.S. Phase 1 Study Of Protollin For Treatment Of Alzheimer's Disease